Stock Comparison
JNJ vs KO: Which Is the Better Pick in 2026?
A head-to-head comparison of Johnson & Johnson and The Coca-Cola Company covering yield, cost, risk, and income potential.
Data updated August 21, 2026
Visual comparison
Key metrics
Projected income on $10K
Projections assume the current yield and share price remain constant. Actual results will vary.
Total returns
JNJ has outpaced KO over the trailing twelve months, posting a 54.00% total return against 32.50%. The lead holds up over 10 years too: JNJ has compounded at 11.41% a year, against 11.03% for KO. Figures are total returns: price change plus every distribution reinvested.
| Symbol | YTD | 1Y | 3Y | 5Y | 10Y | Since Jan 1962 | Volatility | Sharpe | Sortino | Max drawdown |
|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | 31.02% | 54.00% | 20.56% | 11.50% | 11.41% | 13.13% | 17.9% | 0.80 | 1.16 | -14.4% |
| KO | 33.56% | 32.50% | 18.08% | 13.27% | 11.03% | 12.20% | 16.5% | 0.74 | 1.12 | -15.5% |
Total return with all distributions reinvested on the ex-dividend date, split-adjusted, as of August 21, 2026. YTD and 1Y are cumulative; longer windows are annualized. “Since Jan 1962” measures every fund from January 2, 1962 — the youngest fund's first trading day — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the trailing 3 years. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the trailing 3 years) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Side-by-side snapshot
| Metric |  JNJ |  KO |
|---|---|---|
| Full name | Johnson & Johnson | The Coca-Cola Company |
| Issuer | — | — |
| Last Close | $270.24 as of August 21, 2026 | $91.10 as of August 21, 2026 |
| Distribution yield | 1.90% | 2.30% |
| Distribution Safety Score™ | 100 | 99 |
| Expense ratio | — | — |
| AUM | — | — |
| Distribution frequency | Quarterly | Quarterly |
| Underlying index | — | — |
| Objective | Researches, develops, manufactures, and sells healthcare products including pharmaceuticals, medical devices, and consumer health products worldwide. | Manufactures, distributes, and markets nonalcoholic beverage concentrates, syrups, and finished beverages worldwide. |
| Asset class | Equity | Equity |
| Inception date | N/A | N/A |
| Beta | 0.231 | 0.342 |
| Last dividend | $1.3400 | $0.5300 |
| Ex-dividend date | 08/25/2026 | 09/15/2026 |
Bottom lineJNJ and KO are nearly interchangeable — both offer very similar pharmaceuticals & medical devices exposure with very similar cost and risk. Neither charges a fund expense ratio, so the decision rests on business fundamentals, payout history, and valuation.
Income calculator
See how much monthly income a hypothetical investment would generate in each stock at current yields.
Want to go deeper?
Add these stocks to a sample portfolio and forecast your dividend income over 5+ years — free to start, no credit card.
Quick verdict
JNJ (Johnson & Johnson) and KO (The Coca-Cola Company) are both quarterly-pay dividend-paying stocks, but they take different approaches.
KO offers the higher yield at 2.30% vs 1.90% for JNJ. A higher yield means more current income per dollar invested, though it may come with different risk characteristics.
Still deciding? Track JNJ & KO for free
Create a free Dividend Vision account to keep them on a watchlist, get notified when they declare dividends, and see how much income they would add to your portfolio.
Deep dive
Yield & income
On a $10,000 investment, JNJ would generate roughly $15.83/month, while KO would produce $19.17/month, at current distribution rates. Both pay quarterly distributions.
Strategy & risk
JNJ is a stock built around pharmaceuticals & medical devices exposure, while KO is a stock built around beverages exposure. Beta is 0.231 for JNJ and 0.342 for KO, making JNJ the less volatile of the two by this measure.
Security details
JNJ (Johnson & Johnson) is a stock. KO (The Coca-Cola Company) is a stock.
Enjoyed this page?
Do us a favor — if you found this comparison useful, please share it with a friend researching dividend investments.
Frequently asked questions
What is the current distribution yield for JNJ and KO?
JNJ currently distributes 1.90% and KO 2.30%, based on fund data updated August 2026. Distribution yield moves with both the payout and the share price, so check the as-of date before relying on either figure.
Is JNJ or KO better for dividend income?
It depends on your goals. KO currently offers the higher distribution yield, which means more income per dollar invested. However, a lower-yield fund may offer better total return or lower volatility. Consider your time horizon and risk tolerance.
What is the difference between JNJ and KO?
JNJ (Johnson & Johnson) is a stock built around pharmaceuticals & medical devices exposure, while KO (The Coca-Cola Company) is a stock built around beverages exposure. They are issued by — and — respectively.
Can I hold both JNJ and KO?
Yes — nothing prevents holding both. Whether the combination actually diversifies depends on how much the underlying exposures overlap, which isn't fully measurable from the data on this page; review each security's holdings, sector, and strategy before treating them as complementary.
Is JNJ or KO safer?
By Dividend Vision's Distribution Safety Score — a rules-based 0–100 estimate of how resilient a distribution looks, where higher is safer — they are effectively tied: JNJ scores 100, KO scores 99. Neither has a clear safety edge on that measure. No score makes an investment risk-free — treat this as a screening signal, not a guarantee.
How much income does $10,000 in JNJ vs KO generate?
At current rates, $10,000 in JNJ would generate roughly $15.83 per month ($190.00 annually). The same in KO would produce about $19.17 per month ($230.00 annually).
Which has performed better historically, JNJ or KO?
JNJ has outpaced KO over the trailing twelve months, posting a 54.00% total return against 32.50%. The lead holds up over 10 years too: JNJ has compounded at 11.41% a year, against 11.03% for KO. Figures are total returns: price change plus every distribution reinvested. Past performance does not guarantee future results.
More comparisons to explore
People also compare KO with
Popular comparisons
JNJ vs KO — at a glance
Generated August 15, 2026.
Figures quoted in this analysis are from its generation date and may lag the live snapshot table above, which always shows the latest data.
Overview
Johnson & Johnson and Coca-Cola are two of the longest-tenured dividend-paying stocks in the market, both with roots tracing back to the early 1960s. JNJ operates in pharmaceuticals, medical devices, and consumer health, while KO manufactures and distributes nonalcoholic beverages globally. The key distinction: JNJ is a lower-volatility healthcare play with defensive characteristics, whereas KO offers a higher current yield backed by a consumer staples business with slightly more systematic risk.
How they differ
JNJ's beta of 0.231 versus KO's 0.342 reveals the first split: JNJ moves less than half the market's typical swing, making it the more defensive choice; KO is also defensive but carries roughly 50% more market sensitivity. On yield, KO's 2.40% distribution rate edges JNJ's 1.99%—a 41-basis-point gap that compounds over time. Both pay quarterly dividends. JNJ's pharmaceutical and medical-device focus ties earnings to drug development cycles, patent cliffs, and healthcare policy; KO's beverage concentration means earnings track consumer discretionary spending and commodity input costs (sugar, aluminum). At $260.35 per share, JNJ trades at a higher absolute price than KO at $87.71, but that's a structural feature, not a valuation signal on its own.
Who each is best for
JNJ: Fits investors seeking minimal portfolio volatility and willing to accept lower current yield in exchange for the stability of a diversified healthcare conglomerate with exposure to aging demographics and recurring drug demand.
KO: Fits investors who prioritize current income and can tolerate slightly higher market sensitivity in exchange for a yield premium and exposure to global consumer staples demand across multiple beverage categories.
Key risks to know
- Patent and regulatory risk (JNJ): Pharmaceutical revenue depends on patent protection; expiration of key drugs can drive sharp earnings declines. Healthcare policy changes also affect pricing power and reimbursement rates.
- Currency and commodity exposure (KO): Coca-Cola derives significant revenue internationally, so foreign exchange swings can pressure reported earnings. Sugar and aluminum prices directly affect cost of goods and margins.
- Lower systematic volatility can mask idiosyncratic risk: Both stocks' low betas reflect their defensive positioning but don't protect against company-specific operational failures, supply-chain disruptions, or management missteps.
- Dividend sustainability depends on earnings growth: Both stocks' high payout ratios mean dividend increases depend on underlying business growth; flat or negative earnings can eventually pressure distributions.
Bottom line
If you want maximum downside cushioning and can live with lower yield, JNJ's lower beta and pharmaceutical moat stand out. If you prioritize income and accept a bit more market sensitivity, KO's 41-basis-point yield advantage and consumer staples resilience merit consideration. Past performance doesn't predict future results; evaluate each company's competitive position and earnings trajectory in your own planning timeline.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
Learn the method
The metrics behind this comparison, explained in the Academy.
Still deciding? Compare them against your own portfolio
See how each stock fits alongside your real holdings — forecast future income, analyze overlap, and gauge risk. Start a free 7-day Dividend Vision trial and make the call with your full portfolio in view.